Monitoring individual response to brain-tumour chemotherapy: proton MR spectroscopy in a patient with recurrent glioma after stereotactic radiotherapy

被引：16

作者：

Lichy, MP

Bachert, P

Henze, M

Lichy, CM

Debus, J

Schlemmer, HP

机构：

[1] German Canc Res Ctr, Dept Radiol, D-69120 Heidelberg, Germany

[2] Univ Heidelberg, Dept Nucl Med, D-69120 Heidelberg, Germany

[3] Univ Heidelberg, Dept Neurol, D-69120 Heidelberg, Germany

[4] Univ Heidelberg, Radiol Clin, D-69120 Heidelberg, Germany

[5] Univ Tubingen, Radiol Clin, D-72076 Tubingen, Germany

来源：

NEURORADIOLOGY | 2004年 / 46卷 / 02期

关键词：

proton magnetic resonance spectroscopy; magnetic resonance spectroscopic imaging chemotherapy; PCV; brain tumour; radiotherapy; positron-emission tomography;

D O I：

10.1007/s00234-003-1116-8

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Since antineoplastic activity varies, sensitive methods for individual assessment of efficacy are needed. We demonstrate the clinical value of MR spectroscopy in monitoring chemotherapy in a patient with recurrent glioma after stereotactic radiotherapy. Diagnostic imaging before and after chemotherapy included contrast-enhanced MRI, single-voxel proton MR spectroscopy (H-1 MRS), H-1 MR spectroscopic imaging (H-1 SI), and fluorodeoxyglucose (FDG) positron-emission tomography (PET). A significant decrease in choline signal intensity was observed 2 months after chemotherapy indicating tumour chemosensitivity, in line with tumour shrinkage on MRI and decreased uptake of FDG. Assessment of early response by MRS may help to improve treatment protocols in other patients.

引用

页码：126 / 129

页数：4

共 10 条

[1]

Chan YL, 1999, J MAGN RESON IMAGING, V10, P130, DOI 10.1002/(SICI)1522-2586(199908)10:2<130::AID-JMRI4>3.0.CO

[2]

2-R

[3]

KAPPELLE AC, 2001, J CLIN ONCOL, V19, P509

[4]

Langleben DD, 2000, J NUCL MED, V41, P1861